Johnson & Johnson (JNJ) Given Consensus Recommendation of “Hold” by Analysts
Shares of Johnson & Johnson (NYSE:JNJ) have earned a consensus rating of “Hold” from the twenty-one research firms that are covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $133.79.
Several equities analysts have recently weighed in on JNJ shares. J P Morgan Chase & Co lifted their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 16th. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a research note on Monday. Jefferies Group LLC set a $145.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Tuesday, August 15th. Wells Fargo & Company reiterated a “market perform” rating and issued a $135.00 target price (up previously from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th. Finally, BidaskClub downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 1st.
Shares of Johnson & Johnson (JNJ) traded down 0.27% on Friday, hitting $131.39. 4,334,862 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $132.79 and its 200 day moving average is $129.43. The firm has a market cap of $352.65 billion, a P/E ratio of 22.23 and a beta of 0.79. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. Johnson & Johnson also was the target of unusually large options trading activity on Wednesday. Investors bought 11,192 put options on the stock. This is an increase of approximately 244% compared to the typical daily volume of 3,249 put options.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.74 earnings per share. On average, equities analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.56%. Johnson & Johnson’s payout ratio is presently 56.76%.
In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.
A number of institutional investors have recently made changes to their positions in JNJ. Harding Loevner LP bought a new stake in Johnson & Johnson during the second quarter valued at approximately $106,000. Lenox Wealth Advisors Inc. lifted its position in Johnson & Johnson by 0.7% during the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after purchasing an additional 6 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. IHT Wealth Management LLC lifted its position in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after purchasing an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new stake in Johnson & Johnson during the second quarter valued at approximately $124,000. Institutional investors and hedge funds own 65.90% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.